Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Evaluating credit card rewards is crucial for maximizing value. Learn which options provide the best returns for your spending.
28,180 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Cava's yearly revenue just crossed the $1 billion mark, signaling a major milestone for the fast-casual chain. This a...
Midweek is a prime time to refresh your investment plan. This Wednesday Reads guide breaks down tax-smart moves, mark...
Micron's memory leadership and AI-ready HBM4 shipments clash with Intel's restructuring effort and foundry bets. As A...
A biotech stock has surged 355%, catching the eye of every investor from day traders to pension funds. A prominent he...
SoFi Technologies popped on June trading as institutional buyers chased continued innovation. This deep dive explains...
Five infrastructure REITs are quietly powering AI workloads behind the scenes, but their stock returns haven’t kept p...
Can Walmart transform into a true millionaire-maker stock? This practical guide weighs stability, growth, and dividen...
On Mar. 12, a niche tech partnership caused a notable move in the stock market today landscape. Ondas jumped after li...
Ripple-backed Evernorth adds OpenAI leadership to its board as XRP hovers around $1.40 in preparation for a Nasdaq li...
What’s going with stock? AMD is riding a data center and AI wave. This guide breaks down the drivers, risks, and real...
Apple is leaning into a capital-light AI model that runs on-device and with trusted partners. This story explains why...